Komori
ReproCELL (4978) · RiskMitigated

Risk of difficulty securing highly skilled personnel and falling short of recruitment targets

First written in FY2017. 4 of 5 entries say "Mitigated", first in FY2018. Latest entry: FY2020.

5entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017MitigatedFY2018 – FY20202017: 120172018: 220182019: 120192020: 12020
Same theme, other companies
Difficulty Securing, Developing and Retaining Specialized and Highly Skilled IT PersonnelA theme 540 companies write about · 555 as a headwind · 4 as a tailwind

The whole theme swung hardest in 2026: 34 of 109 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 190 companies compared. The sentences above are computed from all 190.Comparing 200 of the theme's 559 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2020MitigatedAnnual report

    「The company is working to retain outstanding personnel over the long term, including by introducing incentive systems for outstanding directors and personnel at the general manager level of each company, including overseas subsidiaries, and is also actively recruiting new outstanding personnel.」

    The company has reaffirmed measures to retain highly skilled personnel over the long term through incentive systems and new hiring in response to the risk of outflows of highly skilled personnel and failure to meet recruitment targets.
  2. FY2020-Q2MitigatedAnnual report

    「The transfer restriction period has been set at 2 years in order to share the benefits and risks of share-price fluctuations with shareholders and achieve over the medium term the purpose of introducing this system, namely to further increase motivation to contribute to share-price appreciation and enhanced corporate value.」

    The company has reaffirmed its approach of encouraging long-term retention and a willingness to contribute to enhancing corporate value by additionally granting restricted stock compensation to officers and employees and setting a 2-year transfer restriction.
  3. FY2019-Q1MitigatedAnnual report

    「The restricted transfer period has been set at 2 years in order to achieve over the medium term the purpose of introducing this system, namely to share the benefits and risks of share price movements with shareholders and further increase their motivation to contribute to higher share prices and corporate value.」

    As a measure to encourage the long-term retention of personnel and their willingness to contribute to enhancing corporate value, the company has introduced restricted stock compensation for directors, employees and others, with a 2-year transfer restriction.
  4. FY2018MitigatedAnnual report

    「We are working to retain talented personnel over the long term, including directors and personnel at general manager level at each company, including overseas subsidiaries, by introducing stock option plans and other measures. We are also actively recruiting new talented personnel.」

    As specific measures to address the risk of losing highly skilled personnel and failing to recruit sufficient personnel, the company cited long-term retention through stock options and new recruitment.
  5. FY2017First statedAnnual report

    「However, if the securing and recruitment of talented personnel do not proceed as planned, this may affect our group’s operating performance and financial condition.」

    The company described separately the risk that securing and recruiting personnel with advanced specialized knowledge, skills and experience is a prerequisite for its growth strategy.
Moved together

"Raising Funds for Cell Therapy Product Development and Clinical Trials through the 12th Series of Stock Acquisition Rights" moved the same way as this thread, in the same document, in 3 of its 5 moves.

333322★123456
  1. ★This thread
  2. 1Raising Funds for Cell Therapy Product Development and Clinical Trials through the 12th Series of Stock Acquisition Rights3×
  3. 2Exclusive development and marketing of Stemchymal® in Japan3×
  4. 3Global expansion leveraging sales channels in Japan, the US and Europe3×
  5. 4Funding Needs and Financing Risk Associated with Research and Development and Capital Investment3×
  6. 5Differentiation through a broad lineup of research reagents, cell products and contract services2×
  7. 6Clinical-grade development of research reagents and sales of products for regenerative medicine2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for ReproCELL yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of difficulty securing highly skilled personnel and falling short of recruitment targets | ReproCELL Incorporated (4978) | Komori